Thyroid Health and Development: How Hypothyroidism Impacts Your Baby's Future
"Uncover the critical link between thyroid function during pregnancy and your child's neurological development, and what you can do to ensure a healthy start."
During pregnancy, thyroid hormones (THs) play a vital role in fetal development, particularly in the construction of the cytoskeleton – the structural framework within cells. This system, composed of microtubules (Tubulin), microfilaments (Actin), and intermediate filaments, is essential for neural cell shape, neuronal migration, and overall brain development. When thyroid hormone levels are insufficient, especially due to maternal hypothyroidism, the consequences can be far-reaching.
Research indicates that THs regulate and reorganize the cytoskeleton through non-genomic actions. These hormones also control the expression of the extracellular matrix (ECM) and adhesion molecules, crucial for neuronal migration and development. These include vital substances like tenascin-C, neural cell adhesion molecule (N-CAM), reelin and dab1, laminin, and fibronectin. These ECM and adhesion molecules are building blocks and must be available.
A mother's thyroid hormones directly influence the expression of genes related to neuronal migration, neurite branching, astrocytic cytoskeletal proteins, cell cycle regulators, neurotrophins and their receptors, and extracellular matrix proteins within the fetal brain. Ensuring adequate thyroid hormone levels is thus paramount for healthy neurological development.
How Common Is Hypothyroidism in Pregnancy?
Endotext reports overt hypothyroidism in 0.3–0.5% of pregnancies and subclinical hypothyroidism in 2–3%. A 2023 study of 17,177 pregnant women in Lleida, Spain, found an annual hypothyroidism prevalence of 5.7–7.1%, showing that reported rates can vary by population and definition. Overt hypothyroidism may be subtle and difficult to distinguish from normal pregnancy symptoms. Pregnancy can also enlarge the thyroid, particularly in iodine-deficient regions.
Why Diagnosis Requires Care
In general, evaluating hypothyroidism during pregnancy requires attention to symptoms as well as thyroid-related laboratory findings. Interpretation can be difficult because pregnancy itself changes the body and can produce symptoms that resemble thyroid dysfunction. The available material does not establish one universally accepted screening or treatment approach, so clinical decisions may require individualized assessment.
Evolving Understanding
Understanding of thyroid health in pregnancy has developed from recognizing maternal symptoms to focusing on the thyroid hormone requirements of both mother and developing baby. Earlier observations helped establish that inadequate maternal thyroid hormone could affect fetal development. The available material does not provide enough historical detail to identify specific dates or foundational discoveries with confidence.
The Chilling Effects of Hypothyroidism on Brain Development
Maternal hypothyroidism can significantly reduce the expression of Glial Fibrillary Acidic Protein (GFAP) in the fetal brain during late gestation. Studies on neonatal hypothyroid rats reveal disorganized actin fibers in the cerebellum, alongside disruptions in laminin. These abnormalities can alter cellular cytoskeleton development, impacting microtubule protein synthesis, axonal transport, neuronal outgrowth, and behavior. This disruption of axonal transport has downstream impacts.
- Disrupted Cellular Structure: Hypothyroidism leads to disorganized actin fibers and disruptions in laminin, critical components of the brain's cellular structure.
- Impaired Protein Synthesis: The condition affects the synthesis of microtubule proteins, vital for axonal transport and neuronal development.
- Behavioral Changes: Resulting abnormalities impact neuronal outgrowth and behavior, leading to potential developmental delays.
An Active Research Area
Recent research continues to examine how hypothyroidism during pregnancy relates to maternal and fetal outcomes. Reviews and studies are also assessing how pregnancy-related physiological changes affect diagnosis and treatment decisions. Because the available material does not identify specific recent findings, the direction and clinical significance of this research should be interpreted cautiously.
Risks and Remaining Uncertainty
Sources consistently describe untreated thyroid dysfunction in pregnancy as a potential risk for both mother and baby, with reported concerns including pre-eclampsia, prematurity, congenital abnormality, and adverse fetal outcomes. Diagnosis relies on serum TSH and free thyroxine levels, but pregnancy-related physiological changes complicate interpretation. For women already known to have hypothyroidism, one review reports that increasing the thyroxine dose by 20–40% when pregnancy is confirmed usually helps maintain a euthyroid state. Earlier studies also reported lower IQ and impaired psychomotor development among children born to mothers with hypothyroidism, although these findings describe early research rather than a guaranteed outcome for every child.
Different Clinical Contexts
Hypothyroidism in pregnancy can involve different clinical situations, including previously recognized disease and thyroid dysfunction identified during pregnancy. The available material suggests that diagnosis and management may be more complicated during pregnancy because normal physiological changes affect hormone levels. Without subsection-specific comparative evidence, firm conclusions about which subgroup faces greater risk or benefits most from treatment would be premature.
Future Directions: Can We Reverse the Damage?
The window for thyroid hormone-dependent regulation of these processes is primarily limited to pre- and perinatal life. Thyroid disorders during development can disrupt the cytoskeleton system, mitochondrial functions, and gene expression. Further research is needed to determine if normalizing circulating TH levels can prevent disturbances in fetal brain cytoskeletal protein expression. This could pave the way for interventions that mitigate the neurological impacts of thyroid imbalances during pregnancy, ensuring healthier outcomes for future generations.
An Unsettled Treatment Debate
Evidence about whether subclinical hypothyroidism causes adverse pregnancy outcomes, and whether levothyroxine prevents them, remains unclear. As a result, recommendations for managing subclinical hypothyroidism during pregnancy are inconsistent. Recent work has specifically examined periconceptional levothyroxine treatment, including cases with TSH levels above 2.5 mU/L, to identify who may benefit. Reviews describe this as an evolving area that incorporates both recent research and landmark studies.
Updated Guidance for 2026
The American Thyroid Association published updated 2026 guidelines for thyroid disease during preconception, pregnancy, and the postpartum period. The update follows substantial new clinical and scientific evidence since the ATA's 2017 guidelines. Reports describing the change characterize it as the first major rewrite of the pregnancy-related thyroid guidance in nearly a decade. The new recommendations are intended to provide updated, evidence-based direction for diagnosis and management.
Greater Hormonal Demands
Maternal thyroid hormone production demands increase by approximately 50% during pregnancy, according to a 2025 review. Meeting that demand requires an adequate iodine supply for thyroid-hormone biosynthesis and the absence of significant thyroid disease. These physiological requirements help explain why pregnancy creates important management challenges for women with hypothyroidism. Clinical decisions must account for the specific issues that arise when pre-existing or newly occurring hypothyroidism overlaps with pregnancy.
Adherence and Outcomes
A 2025 study evaluated pregnancy complications among women with overt hypothyroidism, defined in its report as TSH of at least 10, using data from 259,897 live-birth pregnancies in Clalit Health Services between 2013 and 2022. A clinical case report emphasized the connection between maternal and fetal health and highlighted medication adherence and thyroid control during pregnancy. Other recent studies have examined subclinical hypothyroidism and perinatal outcomes in specific populations, including the Middle East. These findings support the practical importance of continued monitoring and treatment, while the reported study designs do not by themselves establish that every complication is caused by hypothyroidism.